Skip to main content

Advertisement

SpringerLink
Log in

Clinical and molecular prognostic factors in follicular lymphoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The observed variability in the clinical course of follicular lymphoma (FL), along with the diverse range of therapeutic options available, necessitates accurate prognostic stratification of the individual patient. A number of clinical, laboratory, and pathologic parameters have been associated with both good and poor risk disease; in some instances these have been incorporated into readily calculable prognostic indices. With new insights into disease biology and the resulting identification of biomarkers that have arisen from the analysis of both the genome and the transcriptome, more accurate individualization of prognosis will be realized. At present the clinical application of such biomarkers, however, remains largely in its infancy. This review examines the clinical and molecular prognostic features that have been identified as of value in FL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Decaudin D, Lepage E, Brousse N, et al.: Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol 1999, 17:2499–2505.

    PubMed  CAS  Google Scholar 

  2. Gallagher CJ, Gregory WM, Jones AE, et al.: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986, 4:1470–1480.

    PubMed  CAS  Google Scholar 

  3. Cameron DA, Leonard RC, Mao JH, Prescott RJ: Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leuk Lymphoma 1993, 10:89–99.

    Article  PubMed  CAS  Google Scholar 

  4. Gospodarowicz MK, Bush RS, Brown TC, Chua T: Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984, 10:489–497.

    PubMed  CAS  Google Scholar 

  5. Denham JW, Denham E, Dear KB, Hudson GV: The follicular non-Hodgkin’s lymphomas—II. Prognostic factors: what do they mean? Eur J Cancer 1996, 32A:480–490.

    Article  PubMed  CAS  Google Scholar 

  6. Federico M, Vitolo U, Zinzani PL, et al.: Prognosis of follicular lymphoma:a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000, 95:783–789. Prognostic variables from a large number of patents with FL were collated to derive the Italian Lymphoma Intergroup Index (ILI).

    PubMed  CAS  Google Scholar 

  7. Aviles A, Neri N, Cuadra I, et al.: Lack of prognostic factors in follicular lymphoma. Leuk Lymphoma 2003, 44:143–147.

    Article  PubMed  CAS  Google Scholar 

  8. Leonard RC, Hayward RL, Prescott RJ, Wang JX: The identification of discrete prognostic groups in low grade non-Hodgkin’s lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991, 2:655–662.

    PubMed  CAS  Google Scholar 

  9. Solal-Celigny P, Roy P, Colombat P et al.: Follicular lymphoma international prognostic index. Blood 2004, 104:1258–1265. Describes the generation and validation of the FLIPI.

    Article  PubMed  CAS  Google Scholar 

  10. Maartense E, Le Cessie S, Kluin-Nelemans HC, et al.: Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’s lymphoma registry. Ann Oncol 2002, 13:1275–1284.

    Article  PubMed  CAS  Google Scholar 

  11. Romaguera JE, McLaughlin P, North L, et al.: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991, 9:762–769.

    PubMed  CAS  Google Scholar 

  12. Bastion Y, Berger F, Bryon PA, et al.: Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991, 2(Suppl 2):123–129.

    PubMed  Google Scholar 

  13. Litam P, Swan F, Cabanillas F, et al.: Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991, 114:855–860.

    PubMed  CAS  Google Scholar 

  14. Lopez-Guillermo A, Montserrat E, Bosch F, et al.: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994, 12:1343–1348.

    PubMed  CAS  Google Scholar 

  15. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987–994.

  16. Bastion Y, Coiffier B: Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 1994, 12:1340–1342.

    PubMed  CAS  Google Scholar 

  17. Hermans J, Krol AD, van Groningen K, et al.: International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995, 86:1460–1463.

    PubMed  CAS  Google Scholar 

  18. The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997, 89:3909–3918.

  19. Foussard C, Desablens B, Sensebe L, et al.: Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol 1997, 8(Suppl 1):49–52.

    Article  PubMed  Google Scholar 

  20. Arcaini L, Colombo N, Passamonti F, et al.: Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006, 30:277–282.

    Article  PubMed  Google Scholar 

  21. Perea G, Altes A, Montoto S, et al.: Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005, 16:1508–1513. An interesting comparison of prognostic indices in a large population.

    Article  PubMed  CAS  Google Scholar 

  22. Plancarte F, Lopez-Guillermo A, Arenillas L, et al.: Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006, 76:58–63.

    Article  PubMed  Google Scholar 

  23. Montoto S, Lopez-Guillermo A, Altes A, et al.: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004, 15:1484–1489.

    Article  PubMed  CAS  Google Scholar 

  24. Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447–8452.

    Article  PubMed  CAS  Google Scholar 

  25. Swenson WT, Wooldridge JE, Lynch CF, et al.: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005, 23:5019–5026.

    Article  PubMed  Google Scholar 

  26. Nathwani BN, Harris NL, Weisenburger D, {eeat al.}: Follicular lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited byJaffe ES, Harris NL. Lyon, France: IARC Press; 2001:162–167.

    Google Scholar 

  27. Martin AR, Weisenburger DD, Chan WC, et al.: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995, 85:3671–3678.

    PubMed  CAS  Google Scholar 

  28. Jaffe ES, Harris NL (eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

    Google Scholar 

  29. Ganti AK, Weisenburger DD, Smith LM, et al.: Patients with grade 3 follicular lymphoma have prolonged relapsefree survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006, 17:920–9277.

    Article  PubMed  CAS  Google Scholar 

  30. Miller TP, LeBlanc M, Grogan TM, Fisher RI: Follicular lymphomas: do histologic subtypes predict outcome? Hematol Oncol Clin North Am 1997, 11:893–900.

    Article  PubMed  CAS  Google Scholar 

  31. Chau I, Jones R, Cunningham D, et al.: Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003, 89:36–42.

    Article  PubMed  CAS  Google Scholar 

  32. Bartlett NL, Rizeq M, Dorfman RF, et al.: Follicular largecell lymphoma: intermediate or low grade? J Clin Oncol 1994, 12:1349–1357.

    PubMed  CAS  Google Scholar 

  33. Rodriguez J, McLaughlin P, Fayad L, et al.: Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973–1981. Ann Oncol 2000, 11:1551–1556.

    Article  PubMed  CAS  Google Scholar 

  34. Wendum D, Sebban C, Gaulard P, et al.: Follicular largecell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997, 15:1654–1663.

    PubMed  CAS  Google Scholar 

  35. Anderson JR, Vose JM, Bierman PJ, et al.: Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993, 11:218–224.

    PubMed  CAS  Google Scholar 

  36. Hans CP, Weisenburger DD, Vose JM, et al.: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003, 101:2363–2367.

    Article  PubMed  CAS  Google Scholar 

  37. Hu E, Weiss LM, Hoppe RT, Horning SJ: Follicular and diffuse mixed small-cleaved and large-cell lymphoma-a clinicopathologic study. J Clin Oncol 1985, 3:1183–1187.

    PubMed  CAS  Google Scholar 

  38. Ezdinli EZ, Costello WG, Kucuk O, Berard CW: Effect of the degree of nodularity on the survival of patients with nodular lymphomas. J Clin Oncol 1987, 5:413–418.

    PubMed  CAS  Google Scholar 

  39. Goodlad JR, Batstone PJ, Hamilton D, Hollowood K: Follicular lymphoma with marginal zone differentiation: cytogenetic findings in support of a high-risk variant of follicular lymphoma. Histopathology 2003, 42:292–298.

    Article  PubMed  CAS  Google Scholar 

  40. Nathwani BN, Anderson JR, Armitage JO, et al.: Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin’s Lymphoma Classification Project. Hum Pathol 1999, 30:263–268.

    Article  PubMed  CAS  Google Scholar 

  41. Wang SA, Wang L, Hochberg EP, et al.: Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005, 29:1490–1496.

    Article  PubMed  Google Scholar 

  42. Macartney JC, Camplejohn RS, Morris R, et al.: DNA flow cytometry of follicular non-Hodgkin’s lymphoma. J Clin Pathol 1991, 44:215–218.

    PubMed  CAS  Google Scholar 

  43. Koster A, van Krieken JH, Mackenzie MA, et al.: Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005, 11:154–161.

    PubMed  CAS  Google Scholar 

  44. Canioni D, Brice P, Lepage E, et al.: Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d’Etude des Lymphomes Folliculaires. Br J Haematol 2004, 126:364–371.

    Article  PubMed  Google Scholar 

  45. Cullen MH, Lister TA, Brearley RI, et al.: Histological transformation of non-Hodgkin’s lymphoma: a prospective study. Cancer 1979, 44:645–651.

    Article  PubMed  CAS  Google Scholar 

  46. Hubbard SM, Chabner BA, DeVita VT Jr, et al.: Histologic progression in non-Hodgkin’s lymphoma. Blood 1982, 59:258–264.

    PubMed  CAS  Google Scholar 

  47. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984, 311:1471–1475.

    Article  PubMed  CAS  Google Scholar 

  48. Bastion Y, Sebban C, Berger F, et al.: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997, 15:1587–1594.

    PubMed  CAS  Google Scholar 

  49. Garvin AJ, Simon RM, Osborne CK, et al.: An autopsy study of histologic progression in non-Hodgkin’s lymphomas. 192 cases from the National Cancer Institute. Cancer 1983, 52:393–398.

    Article  PubMed  CAS  Google Scholar 

  50. Armitage JO, Dick FR, Corder MP: Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep 1981, 65:413–418.

    PubMed  CAS  Google Scholar 

  51. Chen CI, Crump M, Tsang R, et al.: Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma. Br J Haematol 2001, 113:202–208.

    Article  PubMed  CAS  Google Scholar 

  52. Williams CD, Harrison CN, Lister TA, et al.: High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001, 19:727–735.

    PubMed  CAS  Google Scholar 

  53. Farinha P, Masoudi H, Skinnider BF, et al.: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169–2174. Immunohistochemical analysis on of a large number of potential biomarkers. The macrophage content of tumors was significant in determining outcome.

    Article  PubMed  CAS  Google Scholar 

  54. Dave SS, Wright G, Tan B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159–2169. This large-scale gene expression study performed by the LLMPP collaboration not only establishes that the pattern of gene expression in the diagnostic lymph node biopsy can predict survival from FL but also that the immune microenviroment may be a critical determinant.

    Article  PubMed  CAS  Google Scholar 

  55. Bilalovic N, Blystad AK, Golouh R, et al.: Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol 2004, 121:34–42.

    Article  PubMed  Google Scholar 

  56. Tilly H, Rossi A, Stamatoullas A, et al.: Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994, 84:1043–1049.

    PubMed  CAS  Google Scholar 

  57. Horsman DE, Connors JM, Pantzar T, Gascoyne RD: Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001, 30:375–382.

    Article  PubMed  CAS  Google Scholar 

  58. Viardot A, Moller P, Hogel J et al.: Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002, 20:4523–4530. A large CGH study of FL with clinical correlates.

    Article  PubMed  Google Scholar 

  59. Biagi JJ, Seymour JF: Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002, 99:4265–4275.

    Article  PubMed  CAS  Google Scholar 

  60. Pezzella F, Jones M, Ralfkiaer E, et al.: Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992, 65:87–89.

    PubMed  CAS  Google Scholar 

  61. Levine EG, Arthur DC, Frizzera G, et al.: Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Intern Med 1988, 108:14–20.

    PubMed  CAS  Google Scholar 

  62. Yunis JJ, Mayer MG, Arnesen MA, et al.: bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989, 320:1047–1054.

    Article  PubMed  CAS  Google Scholar 

  63. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al.: Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999, 93:3081–3087.

    PubMed  CAS  Google Scholar 

  64. Iqbal S, Jenner MJ, Summers KE, et al.: Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance. Br J Haematol 2004, 124:325–328.

    Article  PubMed  CAS  Google Scholar 

  65. Montoto S, Lopez-Guillermo A, Colomer D, et al.: Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. Leuk Lymphoma 2003, 44:71–76.

    Article  PubMed  Google Scholar 

  66. Rambaldi A, Carlotti E, Oldani E, et al.: Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 2005, 105:3428–3433.

    Article  PubMed  CAS  Google Scholar 

  67. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al.: The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998, 91:2955–2960.

    PubMed  CAS  Google Scholar 

  68. Freedman AS, Neuberg D, Mauch P, et al.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999, 94:3325–3333.

    PubMed  CAS  Google Scholar 

  69. Bernell P, Jacobsson B, Liliemark J, et al.: Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B-cell lymphoma: a study by FISH. Br J Haematol 1998, 101:487–491.

    Article  PubMed  CAS  Google Scholar 

  70. Hough RE, Goepel JR, Alcock HE, et al.: Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer 2001, 84:499–503.

    Article  PubMed  CAS  Google Scholar 

  71. Martinez-Climent JA, Alizadeh AA, Segraves R, et al.: Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003, 101:3109–3117.

    Article  PubMed  CAS  Google Scholar 

  72. Lo Coco F, Gaidano G, Louie DC, et al.: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993, 82:2289–2295.

    Google Scholar 

  73. Davies AJ, Lee AM, Taylor C, et al.: A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005, 19:1459–1465.

    Article  PubMed  CAS  Google Scholar 

  74. Matolcsy A, Schattner EJ, Knowles DM, Casali P: Clonal evolution of B cells in transformation from low- to highgrade lymphoma. Eur J Immunol 1999, 29:1253–1264.

    Article  PubMed  CAS  Google Scholar 

  75. Pinyol M, Cobo F, Bea S, et al.: p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 1998, 91:2977–2984.

    PubMed  CAS  Google Scholar 

  76. Yano T, Jaffe ES, Longo DL, Raffeld M: MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992, 80:758–767.

    PubMed  CAS  Google Scholar 

  77. Lossos IS, Alizadeh AA, Diehn M, et al.: Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U SA 2002, 99:8886–8891.

    Article  CAS  Google Scholar 

  78. Zhao WL, Daneshpouy ME, Mounier N, et al.: Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004, 103:695–697.

    Article  PubMed  CAS  Google Scholar 

  79. Bastard C, Deweindt C, Kerckaert JP, et al.: LAZ3 rearrangements in non-Hodgkin’s lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994, 83:2423–2427.

    PubMed  CAS  Google Scholar 

  80. Akasaka T, Lossos IS, Levy R: BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003, 102:1443–1448.

    Article  PubMed  CAS  Google Scholar 

  81. Capello D, Vitolo U, Pasqualucci L, et al.: Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000, 95:651–659.

    PubMed  CAS  Google Scholar 

  82. Lossos IS, Levy R: Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood 2000, 96:635–639.

    PubMed  CAS  Google Scholar 

  83. Szereday Z, Csernus B, Nagy M, et al.: Somatic mutation of the 5′ noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol 2000, 156:1017–1024.

    PubMed  CAS  Google Scholar 

  84. Lossos IS, Jones CD, Zehnder JL, Levy R: A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. Leuk Lymphoma 2001, 42:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  85. Jardin F, Ruminy P, Parmentier F, et al.: Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma. Leukemia 2005, 19:1824–1830.

    Article  PubMed  CAS  Google Scholar 

  86. Bjorck E, Ek S, Landgren O, et al.: High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005, 105:2908–2915. Comparison of gene expression between patients with a favorable or adverse outcome to CHOP chemotherapy identified expression of cyclin B1 as a favorable biomarker.

    Article  PubMed  CAS  Google Scholar 

  87. Glas AM, Kersten MJ, Delahaye LJ, et al.: Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005, 105:301–307. Gene expression profiling was employed to determine the future clinical course of FL with considerable success.

    Article  PubMed  CAS  Google Scholar 

  88. Lossos IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828–1837.

    Article  PubMed  CAS  Google Scholar 

  89. Hans CP, Weisenburger DD, Greiner TC, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275–282.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, EC1A 7BE, London, UK

    Andrew J. Davies MRCP

Authors
  1. Andrew J. Davies MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Davies MRCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, A.J. Clinical and molecular prognostic factors in follicular lymphoma. Curr Oncol Rep 8, 358–367 (2006). https://doi.org/10.1007/s11912-006-0059-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0059-8

Keywords

Search

Navigation